KBY Biotech Indexv0.0.34
Search
← Pipeline|NIA-IIT-954

NIA-IIT-954

Phase 2
By NIAID
Source: Trial-derived·Trials: 1
Modality
Fusion Protein
MOA
RAS(ON)i
Target
PSMA
Pathway
Sphingolipid
Thymoma
Development Pipeline
Preclinical
~Jun 2022
→ ~Sep 2023
Phase 1
~Dec 2023
→ ~Mar 2025
Phase 2
Jun 2025
Phase 2Current
NCT07331972
1,158 pts·Thymoma
2025-06→TBD·Recruiting
1,158 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2
Recruit…
Recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT07331972Phase 2ThymomaRecruiting1158SeizFreq
Competitors (10)
DrugCompanyPhaseTargetMOA
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
AZN-3724AstraZenecaPreclinicalPSMABCMA ADC
DoxacageneSanofiApprovedPSMASHP2i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
GSK-2051GSKPhase 1PSMAEGFRi
GIL-2445Gilead SciencesPhase 2/3PSMAALKi
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
BII-1564BiogenPhase 2PSMABETi
BGN-3859BeiGeneApprovedPSMACD47i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i